INT178489

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 31
Total Number 35
Disease Relevance 25.65
Pain Relevance 0.66

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Kdr) kinase activity (Kdr) cytoplasm (Kdr)
Anatomy Link Frequency
endothelial cells 3
eyes 1
NCI-H460 1
cornea 1
lung 1
Kdr (Mus musculus)
Pain Link Frequency Relevance Heat
imagery 47 97.80 Very High Very High Very High
antagonist 50 91.04 High High
Inflammation 131 80.80 Quite High
cytokine 46 73.60 Quite High
positron emission tomography 8 68.12 Quite High
Taxol 14 63.04 Quite High
Somatostatin 2 14.32 Low Low
cINOD 6 11.60 Low Low
cva 42 5.00 Very Low Very Low Very Low
metalloproteinase 36 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Colon Cancer 46 99.84 Very High Very High Very High
Retinal Neovascularization 4 99.70 Very High Very High Very High
Metastasis 561 99.62 Very High Very High Very High
Corneal Neovascularization 115 99.58 Very High Very High Very High
Cancer 2135 99.48 Very High Very High Very High
Emphysema 57 98.54 Very High Very High Very High
Carcinoma 114 98.20 Very High Very High Very High
Solid Tumor 41 97.84 Very High Very High Very High
Small Cell Lung Cancer 22 96.84 Very High Very High Very High
Non-small-cell Lung Cancer 689 96.72 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Moreover, a significant reduction of both Rac1 and Flk-1 mRNA and protein levels was achieved in pSico-Rac1 or pSico-Flk-1 transduced cells, respectively.
Negative_regulation (reduction) of Flk-1 mRNA
1) Confidence 0.42 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2842301 Disease Relevance 0.43 Pain Relevance 0
The anti-tumor effects can be attributed to the antiangiogenic effects of the substance, which are mediated by the inhibition of the receptor tyrosine kinases Flk-1/KDR (VEGR2), PDGFRbeta and FGFR1.
Negative_regulation (inhibition) of KDR associated with cancer
2) Confidence 0.42 Published 2007 Journal BMC Cancer Section Body Doc Link PMC1832206 Disease Relevance 0.99 Pain Relevance 0
This effect appears to be induced by the antiangiogenic effects of SU6668, which are mediated by the inhibition of the key angiogenic receptor tyrosine kinases Flk-1/KDR, PDGFRbeta and FGFR1.
Negative_regulation (inhibition) of KDR
3) Confidence 0.42 Published 2007 Journal BMC Cancer Section Abstract Doc Link PMC1832206 Disease Relevance 0.97 Pain Relevance 0
The same result was also observed in cultured endothelial cells in vitro [14] and in animal models with retinal neovascularization [13], whereby suppression of Vegfr2 but not Vegfr1 reduced the ability of VEGF to induce vasohibin-1.
Negative_regulation (suppression) of Vegfr2 in endothelial cells associated with retinal neovascularization
4) Confidence 0.37 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2913137 Disease Relevance 0.54 Pain Relevance 0
The inhibition of corneal neovascularization was associated with suppression of Vegfr2 but not Vegfr1 expression by exogenous vasohibin-1 signaling.
Negative_regulation (suppression) of Vegfr2 associated with corneal neovascularization
5) Confidence 0.37 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2913137 Disease Relevance 0.59 Pain Relevance 0
In addition, tissue-specific loss of esVEGFR-2 in mice induces, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting angiogenesis.
Negative_regulation (loss) of esVEGFR in cornea associated with hyperplasia
6) Confidence 0.33 Published 2010 Journal BMC Med Section Body Doc Link PMC2989928 Disease Relevance 0.89 Pain Relevance 0
Moreover, the structurally related compound 676489 (Figure 1A), a selective inhibitor of the type-2 vascular endothelial growth factor receptor type-2 (VEGFR2, Flk), which does not inhibit BMP signaling, did not induce cardiomyogenesis in ES cells under this condition or any of the additional conditions described below (data not shown).
Negative_regulation (inhibitor) of VEGFR2
7) Confidence 0.31 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2483414 Disease Relevance 0 Pain Relevance 0
In addition, dorsomorphin treatment led to sustained decreases in the expression of the vascular marker Flk-1 (Vegfr2) from day 3 to 8 (Figure 5E).
Negative_regulation (decreases) of Flk-1
8) Confidence 0.31 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2483414 Disease Relevance 0.09 Pain Relevance 0
As a positive control (for inhibiting angiogenesis), pSico-Flk-1 was employed for the depletion of Flk-1 (VEGFR2).
Negative_regulation (depletion) of Flk-1
9) Confidence 0.31 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2842301 Disease Relevance 0.43 Pain Relevance 0
As a positive control (for inhibiting angiogenesis), pSico-Flk-1 was employed for the depletion of Flk-1 (VEGFR2).
Negative_regulation (depletion) of VEGFR2
10) Confidence 0.31 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2842301 Disease Relevance 0.43 Pain Relevance 0
Semaxinib (SU5416), an inhibitor of the VEGFR1 and VEGFR2 TKs, has also been studied in combination with INF-?
Negative_regulation (inhibitor) of VEGFR2
11) Confidence 0.27 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.73 Pain Relevance 0
Tumor volume was significantly reduced in the pesVEGFR-2 and pEndo groups, and this reduction was associated with decreased cell proliferation as assessed by BrdU labeling indices.
Negative_regulation (reduced) of pesVEGFR-2 associated with cancer
12) Confidence 0.24 Published 2010 Journal BMC Med Section Body Doc Link PMC2989928 Disease Relevance 1.43 Pain Relevance 0
Survival rates tended to be prolonged in the pesVEGFR-2 and pEndo groups, although this tendency was not statistically significant.
Negative_regulation (prolonged) of pesVEGFR-2
13) Confidence 0.24 Published 2010 Journal BMC Med Section Body Doc Link PMC2989928 Disease Relevance 1.25 Pain Relevance 0
Tumor volume increases were significantly suppressed in the pesVEGFR-2 and pEndo groups from Week 2 to the end of the study as compared to the pVec group.
Negative_regulation (suppressed) of pesVEGFR-2 associated with cancer
14) Confidence 0.24 Published 2010 Journal BMC Med Section Body Doc Link PMC2989928 Disease Relevance 0.99 Pain Relevance 0.11
The average number of all organs with metastasis was significantly decreased in the pesVEGFR-2 and pEndo groups as compared to the pVec group.
Negative_regulation (decreased) of pesVEGFR-2 associated with metastasis
15) Confidence 0.24 Published 2010 Journal BMC Med Section Body Doc Link PMC2989928 Disease Relevance 1.17 Pain Relevance 0
As shown in Figure 1G, the levels were significantly decreased in the pesVEGFR-2 and pEndo groups as compared to the control group.
Negative_regulation (decreased) of pesVEGFR-2
16) Confidence 0.24 Published 2010 Journal BMC Med Section Body Doc Link PMC2989928 Disease Relevance 1.14 Pain Relevance 0.18
In fact, the present study shows that the multiplicity of lymph node metastasis and lung metastatic nodules was significantly reduced in the pesVEGFR-2 group and associated with a decreased number of lymphatic vessels but not blood vessels in mammary carcinomas.
Negative_regulation (reduced) of pesVEGFR-2 in lymphatic vessels associated with carcinoma and metastasis
17) Confidence 0.24 Published 2010 Journal BMC Med Section Body Doc Link PMC2989928 Disease Relevance 0.97 Pain Relevance 0.05
, and Flt-3 were inhibited with IC50 values in the range 40–80 nmol/L whilst VEGFR2 was inhibited with an IC50 of approximately 90 nmol/L.
Negative_regulation (inhibited) of VEGFR2
18) Confidence 0.24 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.12 Pain Relevance 0
At day 7 after corneal NV induction and the start of gene therapy, the inhibitory effect of combined mEndo, msFlk-1, or msTie2 gene therapy was obvious when compared to eyes treated with the vehicle vector or saline (Figure 2, Table 1).
Negative_regulation (effect) of msFlk-1 in eyes
19) Confidence 0.21 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2830023 Disease Relevance 0.40 Pain Relevance 0.14
Inhibition of VEGFR2 autophosphorylation by sorafenib has been investigated in the HUVEC (human umbilical vein endothelial cell) and NIH 3T3 VEGFR2 (murine embryonic fibroblast) cell lines.
Negative_regulation (Inhibition) of VEGFR2 in endothelial cell
20) Confidence 0.20 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.53 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox